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SUMMARY 
 
Environmental factors that act at the intestinal level such as diet, drugs, and microflora have a high 
impact on the pathogenesis of autoimmune Type 1 Diabetes (T1D), but it is still unclear how the gut 
milieu affects autoimmunity outside the intestine. Here we show that peripheral FoxP3+ Treg cell 
differentiation, a mechanism that takes place in the gut and is crucial to maintain systemic immune 
tolerance, is impaired in T1D patients. These results provide the first evidence that gut mucosa 
alteration could predispose to autoimmune T1D by affecting systemic immune regulation. 
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ARTICLE 
 
 In recent decades the incidence rates of autoimmune diseases are noticeably rising and 
nowadays approximately 5% of people in developed countries suffer from one systemic or organ-
specific autoimmune disease1. Type 1 Diabetes (T1D) is a destructive islet ß-cell specific autoimmune 
disease resulting from a yet undefined interaction between genetic and environmental factors2. The 
dramatic increase in T1D incidence recorded in western populations in the past forty years, e.g., three-
fold increase in developed countries3 and +30% in the geographically restricted and highly susceptible 
Sardinian people4, is unlikely related to genetic variations. Environmental factors such as viral infections 
(i.e. enteroviruses and rotaviruses)5,6, reactions to dietary antigens (i.e. cow’s milk and gluten)7-9 and 
microbiota variations10 that act at the intestinal level have been observed in association with, or as risk 
factors for, the development of T1D. In addition, sublinical intestinal abnormalities, such as increased 
permeability to sugars, have been described in patients with T1D and are detectable even before the 
clinical onset of the disease, suggesting that these functional abnormalities may be associated with the 
pathogenesis of T1D11. Although existing evidence is suggestive of a causative link between gut 
environment and the pathogenesis of T1D, it still unclear whether and by which mechanism(s) a 
dysfunction in the intestine does promote autoimmunity elsewhere, i.e., in the pancreatic β-cells and, if it 
does, how this process occurs. A fascinating hypothesis is that systemic and organ-specific 
autoimmune diseases are initiated and, possibly, maintained by virtue of changes in the immune 
regulatory mechanisms originating in the gut and crucial to maintain immune tolerance toward self-
antigens outside the intestine. In facts, the small intestinal mucosa is the preferential site for the 
extrathymic development of regulatory FoxP3+ T cells (Treg cells). Specifically, tolerogenic dendritic 
cells (DCs) residing in the intestinal lamina propria are responsible for extrathymic FoxP3+ Treg cells 
development and expansion12-14. Since FoxP3+ Treg cells are instrumental for maintaining peripheral 
tolerance and preventing autoimmune diseases such as T1D15, it is likely that defects of peripheral Treg 
cell differentiation may favor T1D pathogenesis. Considering how the environment impinges on 
intestinal immunity, it is critical to study immune regulation in the human intestinal mucosa rather than in 
intestinal samples from animals hosted in SPF facilities and, therefore, not exposed to the environment. 
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Hence, to assess whether the gut environment increases susceptibility to autoimmune diabetes by 
altering the peripheral differentiation of FoxP3+ Treg cells, we analyzed the immune regulatory cell 
compartment of the small intestinal mucosa from patients with T1D and controls. We obtained duodenal 
biopsies and blood samples from 53 individuals, including healthy controls, patients with T1D and 
patients with celiac disease (a chronic inflammatory disease of the gut). Age, gender and clinical 
information for each group are summarized in Supplementary Table 1. A Multiparametric FACS 
analysis (see Supplementary Fig. 1 and Methods) showed a significant reduction in the percentage of 
CD4+CD25+FoxP3+CD127- Treg cells in the gut mucosa but not peripheral blood of T1D subjects 
compared to healthy controls (Fig. 1a). Since five out of twelve (40%) T1D patients were also affected 
by celiac disease (see Supplementary Table 2), we performed a multiple groups comparison of gut 
Treg cell percentages in patients affected by T1D only, T1D in association with celiac disease, 
individuals with celiac disease only and healthy controls. As shown in Fig. 1b, the celiac disease did not 
significantly alter the gut Treg cell percentages both in diabetic and non-diabetic individuals and the 
Treg cell reduction was exclusively linked to the diabetic condition (P<0.001 with ANOVA statistical 
test). We verified that the gut CD4+CD25+FoxP3+CD127- T cells that we enumerated belong to the 
human Treg cell subset by documenting their suppressive capacity upon T effector (Teff) cell 
proliferation (Fig. 1c). Interestingly, Treg cells inhibited more efficiently the proliferation of Teff cells from 
the same tissue, i.e., gut Treg cells suppressed gut Teff cells more efficiently than blood Teff cells and 
viceversa  (see Supplementary Fig. 2). Importantly, in the gut mucosa of patients with T1D, the 
quantitative defect regarded exclusively the FoxP3+ Treg cell subset while the percentages of total CD4+ 
T cells as well as other immune populations including NK cells, DCs and γδ T cells were similar to those 
of patients with celiac disease and healthy controls (Fig. 1d). 
 Next, we tested whether the reduced number of gut Treg cells in T1D patients is due to their 
defective differentiation in the intestinal mucosa. A subset of lamina propria DCs (LPDCs) expressing 
the integrin αEβ7 (also called CD103) has the unique capacity to drive the peripheral differentiation of 
FoxP3+ T regulatory cells12-14. Hence, we analyzed the number and functional properties of 
CD103+CD11c+ DCs isolated from gut biopsies of T1D patients and controls. We did not detect any 
difference in the absolute percentage of CD103+CD11c+ DCs (Fig. 2a), nor in the percentages of DCs 
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that expressed the CD103 marker between the three groups (Fig. 2b). Then, we derived 
CD103+CD11c+ DCs from the intestinal mucosa of T1D patients and controls (Supplementary Fig. 3) 
and assessed their ability to induce Treg cell differentiation. CD11c+CD103+ LPDCs  from controls were 
able to convert CD4+CD25- T cells into CD4+CD25+FoxP3+CD127- Treg cells more efficiently than blood 
monocyte-derived DCs (BMDCs) (Fig. 2c). Strikingly, LPDCs from T1D patients completely lacked that 
function and failed to induce FoxP3+ Treg cell differentiation (Fig. 2c). TGF-β was required for LPDCs to 
induce Treg cell differentiation in control individuals (see Supplementary Fig. 4), however it did not 
restore the capacity to generate FoxP3+ Treg cells in LPDCs of T1D patients (Fig. 2c).  
 The identification and characterization of a specific defect of the gut immune regulation 
compartment in patients with T1D contributes to the current understanding of the pathogenesis of the 
disease. Gut T cells continuously travel from the intestinal mucosa to mesenteric and pancreatic lymph 
nodes (PLN)16. Hence, the defective gut differentiation of FoxP3+ Treg cells may directly influence 
immune tolerance towards self-islet antigens in PLN. Further studies are necessary to dissect whether 
the functional defect of LPDCs found in patients with T1D is genetically determined or induced by 
environmental factors. The enteric commensal microflora critically modulates the immune system and 
immune regulation by affecting LPDC function and Treg cells differentiation in the gut17, either directly or 
through epithelial cells18. This raises the hypothesis that the defect of gut immune regulatory 
mechanisms that we have shown in T1D patients may be due to environmental factors, such as diet and 
infections, which alter the gut microflora.  
 
 
Studies were approved by the Ethics Committee of the San Raffaele Scientific Institute, Milan, Italy. All 
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 FIGURE LEGENDS 
 
Figure 1 Selective reduction of FoxP3+ Treg cells in the gut of Type 1 Diabetic patients. a, the 
percentages of CD4+CD25+FoxP3+CD127- Treg cells were measured in the total lymphocyte population 
isolated from the small intestinal mucosa (GUT) or peripheral blood mononuclear cells (PBMC). Briefly, 
at the time of an oesophago-gastro-duodenal endoscopy we collected duodenal biopsies from patients 
with Type 1 Diabetes (T1D, n=12) and healthy controls (HC, n=17). Simultaneously, we collected blood 
samples from the same patients. The regulatory T cells in gut mucosa or PBMC samples were targeted 
by Multiparametric FACS analysis. Data are presented as means + SEM of all experiments. **P = 0.003 
(non-parametric Mann-Whitney test). NS = not significant. b, the percentages of 
CD4+CD25+FoxP3+CD127- Treg cells were compared between patients with T1D (T1D, n=7), patients 
with T1D and celiac disease (T1D+CD, n=5), healthy controls (HC, n=17) and patients with celiac 
disease (CD, n=24). Groups were compared using two-way analysis of variance (ANOVA statistical test, 
P < 0.0001) c, gut CD4+CD25+FoxP3+CD127- T cells were bona-fide Treg cells and showed a 
suppressive capacity similar to that of their blood counterparts. CD4+CD25+FoxP3+CD127- Treg cells or 
CD4+CD25- T effector (Teff) cells isolated from the gut mucosa or PBMC of healthy controls were tested 
in suppression assays. Briefly, Treg or Teff cells were added at 1:1 ratio to responder CSFE-labeled 
CD4+CD25- T cells stimulated with coated anti-CD3 monoclonal antibody, soluble anti-CD28 mAb and 
rhIL-2. The percent of suppression was measured by the percent reduction of proliferation of responder 
T cells (by mean of CSFE dilution). Data are expressed as means + SEM of four independent 
experiments. *P = 0.02 (Student t test). d, Percentages of total CD4+ T cells, NK cells, DCs and γδ T 
cells were measured by Multiparametric FACS analysis in the gut mucosa of patients with T1D, healthy 
controls and patients with celiac disease. Data are means + SEM of all experiments. NS= not significant 
(Student t test). 
 
Figure 2. Lamina propria dendritic cells are present in the small intestine of T1D patients but fail to 
induce Treg cell differentiation. a, percentages of CD103+CD11c+ DCs in the lamina propria of patients 
with T1D, healthy controls and patients with celiac disease. b, percentages of cells that express the gut 
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homing receptor CD103 among different gut lymphocyte subsets in the three groups. c, the capacity of 
lamina propria CD11c+CD103+ DCs of T1D patients and controls to induce Treg cell differentiation was 
evaluated in conversion assays. Blood monocyte-derived DCs (BMDCs) or CD11c+CD103+ lamina 
propria DCs (LPDCs) were obtained from T1D patients (T1D) and controls (CTR) and added to 
autologous naive CD4+CD25- T cells isolated from PBMC and stimulated with soluble anti-human CD3 
mAb in the presence of hrIL-2 and hrTGF-β. Cells were collected after 5 days and FACS analyzed to 
measure percentages of CD4+CD25+FoxP3+CD127- Treg cells. One representative experiment is shown 
on the left inset (cells gated on CD4+CD25-CD127- cells). The right inset shows the mean + S.E.M. of 
CD4+CD25+FoxP3+CD127-Treg cell percentage obtained with different DCs in three (T1D) or four (CTR) 
independent experiments. *P = 0.028 (non-parametric Mann-Whitney statistical test). 
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